-

California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids

PARSIPPANY, N.J.--(BUSINESS WIRE)--Today, Orange County, California, Superior Court Judge Peter Wilson issued a decision finding that Teva did not cause a public nuisance in Orange County, Los Angeles County, Santa Clara County and the City of Oakland and that Teva did not make any false or misleading statements in connection with marketing prescription opioids in California.

While we are pleased that the Court in California made this determination, a clear win for the many patients in the US who suffer from opioid addiction will only come when comprehensive settlements are finalized and resources are made available to all who need them. Teva continues to pursue a national settlement framework as well as to support the business of Teva, which remains dedicated to providing uninterrupted access to affordable medicines throughout the world.

Contacts

IR Contacts

United States
Kevin C. Mannix (215) 591-8912

Israel
Yael Ashman 972 (3) 914-8262

PR Contacts

United States
Kelley Dougherty (973) 658-0237
Yonatan Beker(973) 264 7378

Teva Pharmaceutical Industries Limited

NYSE:TEVA

Release Versions

Contacts

IR Contacts

United States
Kevin C. Mannix (215) 591-8912

Israel
Yael Ashman 972 (3) 914-8262

PR Contacts

United States
Kelley Dougherty (973) 658-0237
Yonatan Beker(973) 264 7378

More News From Teva Pharmaceutical Industries Limited

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

PARSIPPANY, N.J. & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Sanofi today announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program investigating the human IgG1-λ2 monoclonal antibody targeting TL1A for moderate-to-severe IBD. Patient enrollment in the RELIEVE UCCD (ulcerative colitis and Crohn’s disease) Phase 2b trial has completed early due to significant...

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today positive topline results from its Phase 3 SPACE study evaluating the efficacy of AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years. The trial met its primary end point with AJOVY (fremanezumab) achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo. Safety data was consistent wi...

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call wil...
Back to Newsroom